BioSpace News Archive

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the first patient was dosed in its Phase III trial of VV116 for the treatment of moderate to severe COVID-19.

ChromaDex Corp. announced that it was granted an additional continuation patent, U.S. Patent No. 11,274,117, adding to its global patent portfolio surrounding nicotinamide riboside and other nicotinamide adenine dinucleotide precursors.

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that senior leadership plans to present at the following conferences in March.

Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will participate in a fireside chat at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 22, 2022, at 11:00 a.m. ET.

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), today announced it has received notification from the U.S. Food and Drug Administration (“FDA”) that the FDA’s Clinical Hold on AIM’s investigational new drug (“IND”) application for a Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer (AMP-270) has been lifted and the Company may proceed with the study.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced longer-term data from the Phase 3 DERBY and OAKS studies, which showed that intravitreal pegcetacoplan, an investigational, targeted C3 therapy, continued to reduce geographic atrophy (GA) lesion growth and demonstrate a favorable safety profile at month 18 for the treatment of GA secondary to age-related macular degeneration (AMD).

Amicus Therapeutics (Nasdaq: FOLD), today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in adult patients with Pompe disease, an inherited lysosomal storage disorder caused by an enzyme deficiency that leads to accumulation of glycogen (disease substrate) in cells.

Grey Wolf Therapeutics today announced the appointment of Cassian Yee, M.D., to its clinical advisory board.

Karyopharm Therapeutics Inc. today announced that results from the Phase 3 SIENDO study will be presented at the European Society of Medical Oncology’s (ESMO) Virtual Plenary taking place on Thursday, March 17, 2022.

Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) announced today earning a $25 million milestone payment from its collaboration with Janssen Biotech, Inc.